Treatment
Everolimus clinical trials
We’re tracking 57 recruiting studies that include Everolimus, each written for real people, not researchers, below.
Recruiting studies
- NCT02813135RecruitingPhase 1/Phase 2
Targeted cancer treatment chosen by a tumor’s genetic findings
This early-phase trial tests a treatment plan that uses results from genetic testing of your tumor to choose the best targeted therapy. It may help people whose cancer has come back or does not respond to standard treatment by matching treatment to specific tumor changes.
CopenhagenAges Up to 18 years - NCT06658093RecruitingEarly Phase 1
RESTOR: Study of mTOR inhibitors in older adults
This trial tests two FDA-approved drugs, rapamycin and everolimus, to see if they can improve immune function in healthy older adults. You may join if you are generally healthy, live independently, and are between 65 and 90 years old.
San Antonio, TexasAges 65–90 - NCT06718179RecruitingPhase 4
Short vs. 12-month prasugrel and aspirin after a heart attack with a stent
This trial compares taking a shorter course of prasugrel (a blood thinner) plus aspirin after a heart attack versus the standard 12-month course. It aims to see if a shorter duration is just as effective and safer for people who got a specific type of stent (everolimus-eluting).
AalborgAges 18 years+ - NCT06832189RecruitingPhase 1
Testing everolimus and epoetin for liver transplant tolerance
This trial is testing whether a combination of two drugs, everolimus and epoetin, can help liver transplant recipients gradually reduce their anti-rejection medicines. If successful, it may lead to long-term transplant tolerance with fewer side effects.
San Francisco, CaliforniaAges 18 years+ - NCT07002177RecruitingPhase 1/Phase 2
Combination therapy study for ER+/HER2- breast cancer
This trial tests a new drug called FWD1802 combined with other treatments for people with a certain type of advanced breast cancer (ER-positive, HER2-negative). It aims to find better options if standard treatments have stopped working or aren't suitable.
ShanghaiAges 18–75 - NCT07024173RecruitingPhase 3
Study of HRS-8080 for advanced breast cancer
This trial tests a new drug, HRS-8080, against other standard treatments chosen by your doctor for advanced or metastatic breast cancer. It's for women who have already tried 1-2 hormone therapies and are in generally good health.
Guangzhou, GuangdongAges 18–75 - NCT07062965RecruitingPhase 3
PF-07248144 with fulvestrant for HR+ HER2- advanced breast cancer
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
Chandler, ArizonaAges 18 years+ - NCT07191353RecruitingPhase 2
Bone strength study: weight training and a drug for bone health
This trial tests whether combining resistance training with the drug rapamycin can improve bone formation in postmenopausal women who have lower-than-normal bone density but not osteoporosis. It aims to find a new way to strengthen bones and prevent fractures.
Bispebjerg, Region SjællandAges 60–75 - NCT02432560Recruiting
Testing sirolimus for long-term treatment of LAM
This trial studies whether sirolimus can be used safely and works over time for LAM, a rare lung disease. You may be able to join if you already use (or cannot use) certain lung-targeting medicines called mTOR inhibitors, and if you can do regular clinic visits and breathing tests.
Stanford, CaliforniaAges 18 years+
Common questions
- Are there clinical trials studying Everolimus?
- Yes. Clin2 currently lists 57 recruiting studies that include Everolimus, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Everolimus trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Everolimus an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Everolimus or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.